Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2022		2021
Cash and cash equivalents	$	5,434	$	12,586
Restricted cash		1,361		—
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	6,795	$	12,586

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2022 and 2021 is summarized as follows (in thousands):

	December 31,
	2022			2021
Balance, beginning of year	$	79		$	113
Additions		246			71
Expirations and claims satisfied		(118	)		(105	)
Total		207			79
Less current portion within accrued expenses and other current liabilities		(136	)		(59	)
Balance within deferred revenues and other liabilities	$	71		$	20

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2022		2021
Dermatology recurring procedures	$	23,025	$	22,528
Dermatology procedures equipment		13,136		7,449
Total net revenues	$	36,161	$	29,977

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from dermatology recurring procedures (in thousands):

Years ending December 31:
2023	$	1,207
2024		975
2025		384
2026		166
2027		4
	$	2,736

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2022		2021
Restricted stock units		278,004		90,540
Stock options		4,474,714		3,938,613
Common stock warrants		373,626		373,626
		5,126,344		4,402,779